Lung cancer vaccine a dry hole for GlaxoSmithKline
REUTERS – April 2, 2014 – British drug maker GlaxoSmithKline announced that it has stopped its clinical trial of a immunotherapy vaccine for non-small cell lung cancer. The study comparing MAGE-A3 to standard therapy failed to show a significant benefit to people with the disease. The researchers are continuing to look for an effect of the drug on a subgroup of patients with a particular genetic make-up. The drug had previously failed to provide improvement in a clinical trial of melanoma patients.
No comments:
Post a Comment